Willingness to pay for community delivery of antiretroviral treatment in urban Tanzania: a cross-sectional survey.
Community health worker
HIV
Tanzania
differentiated antiretroviral therapy
healthcare financing
willingness to pay
Journal
Health policy and planning
ISSN: 1460-2237
Titre abrégé: Health Policy Plan
Pays: England
ID NLM: 8610614
Informations de publication
Date de publication:
16 Feb 2021
16 Feb 2021
Historique:
accepted:
15
07
2020
pubmed:
22
10
2020
medline:
29
7
2021
entrez:
21
10
2020
Statut:
ppublish
Résumé
Community health worker (CHW)-led community delivery of HIV antiretroviral therapy (ART) could increase ART coverage and decongest healthcare facilities. It is unknown how much patients would be willing to pay to receive ART at home and, thus, whether ART community delivery could be self-financing. Set in Dar es Salaam, this study aimed to determine patients' willingness to pay (WTP) for CHW-led ART community delivery. We sampled ART patients living in the neighbourhoods surrounding each of 48 public-sector healthcare facilities in Dar es Salaam. We asked participants (N = 1799) whether they (1) preferred ART community delivery over standard facility-based care, (2) would be willing to pay for ART community delivery and (3) would be willing to pay each of an incrementally increasing range of prices for the service. 45.0% (810/1799; 95% CI: 42.7-47.3) of participants preferred ART community delivery over standard facility-based care and 51.5% (417/810; 95% CI: 48.1-55.0) of these respondents were willing to pay for ART community delivery. Among those willing to pay, the mean and median amount that participants were willing to pay for one ART community delivery that provides a 2-months' supply of antiretroviral drugs was 3.61 purchasing-power-parity-adjusted dollars (PPP$) (95% CI: 2.96-4.26) and 1.27 PPP$ (IQR: 1.27-2.12), respectively. An important limitation of this study is that participants all resided in neighbourhoods within the catchment area of the healthcare facility at which they were interviewed and, thus, may incur less costs to attend standard facility-based ART care than other ART patients in Dar es Salaam. While there appears to be a substantial WTP, patient payments would only constitute a minority of the costs of implementing ART community delivery. Thus, major co-financing from governments or donors would likely be required.
Identifiants
pubmed: 33083837
pii: 5934090
doi: 10.1093/heapol/czaa088
pmc: PMC7886440
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Langues
eng
Pagination
1300-1308Subventions
Organisme : NCATS NIH HHS
ID : KL2 TR003143
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press in association with The London School of Hygiene and Tropical Medicine.
Références
Lancet HIV. 2016 Aug;3(8):e361-e387
pubmed: 27470028
Health Technol Assess. 2001;5(5):1-186
pubmed: 11262422
AIDS Behav. 2012 Oct;16(7):1988-92
pubmed: 22814571
J Health Econ. 2004 Mar;23(2):237-58
pubmed: 15019754
Soc Sci Med. 2019 Jul;232:238-261
pubmed: 31108330
Lancet. 2018 May 5;391(10132):1799-1829
pubmed: 29678342
AIDS. 2012 Jul 31;26 Suppl 1:S19-30
pubmed: 22781175
Prev Chronic Dis. 2017 Jun 29;14:E51
pubmed: 28662760
J Acquir Immune Defic Syndr. 2010 Dec;55(4):483-90
pubmed: 20683336
PLoS One. 2016 Dec 2;11(12):e0167117
pubmed: 27911921
PLoS One. 2017 Feb 15;12(2):e0172050
pubmed: 28199405
Trop Med Int Health. 2014 Oct;19(10):1198-215
pubmed: 25065882
SAHARA J. 2004 Aug;1(2):107-13
pubmed: 17601016
Ann Glob Health. 2020 Jul 06;86(1):77
pubmed: 32704482
Health Expect. 2018 Feb;21(1):270-278
pubmed: 28805985
Health Serv Res. 2018 Feb;53(1):256-272
pubmed: 27882543
Trop Med Int Health. 2016 Sep;21(9):1124-30
pubmed: 27371814
J Acquir Immune Defic Syndr. 2015 Oct 1;70(2):e52-60
pubmed: 26371611
BMC Health Serv Res. 2017 Feb 22;17(1):160
pubmed: 28228134
Health Policy. 1999 May;47(2):97-123
pubmed: 10538292
Lancet. 2009 Dec 19;374(9707):2080-2089
pubmed: 19939445
AIDS Care. 2018 Dec;30(12):1488-1497
pubmed: 30047280
BMC Med. 2016 Jul 20;14(1):108
pubmed: 27439621
PLoS One. 2015 Sep 01;10(9):e0136664
pubmed: 26327558
PLoS Med. 2018 Sep 19;15(9):e1002659
pubmed: 30231024
Nature. 2015 Dec 3;528(7580):S68-76
pubmed: 26633768
Am J Epidemiol. 2004 Apr 1;159(7):702-6
pubmed: 15033648
BMC Med. 2016 Aug 26;14(1):127
pubmed: 27566531
Glob Health Sci Pract. 2016 Sep 29;4(3):410-21
pubmed: 27651076